GTX, Inc. - NasdaqGM: GTXI


At GTx, we focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body.

We are developing selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy.

To further explore treatments targeting diseases caused by abnormal androgen receptor signaling, we have a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.


175 Toyota Plaza 7th Floor
Memphis, Tennessee 38103
United States

Get Directions

Upgrade Your Listing

Fax: 901-844-8075

Visit Website